
Centene Corporation
NYSE•CNC
CEO: Ms. Sarah M. London
Sector: Healthcare
Industry: Medical - Healthcare Plans
Listing Date: 2001-12-13
Centene Corporation operates as a healthcare enterprise that provides programs and services to under-insured and uninsured families, commercial organizations, and military families in the United States. The company operates through Medicaid, Medicare, Commercial, and Other segments. The Medicaid segment offers health plan coverage, including medicaid expansion, aged, blind, disabled, children's health insurance program, foster care, medicare-medicaid plans, long-term services and support. This segment also provides healthcare products. The Medicare segment offers special needs and medicare supplement, and prescription drug plans. The Commercial segment provides health insurance marketplace product for individual, small, and large group commercials. It also operates clinical healthcare and pharmacies, as well as offers dental and speech therapy services. In addition, the company engages in the government contracts business under the TRICARE program and other healthcare related government contracts. It provides services through primary and specialty care physicians, hospitals, and ancillary providers. Centene Corporation was founded in 1984 and is headquartered in Saint Louis, Missouri.
Contact Information
Centene Plaza, 7700 Forsyth Boulevard, Saint Louis, MO, 63105, United States
314-725-4477
Market Cap
$18.34B
P/E (TTM)
-3.5
vs Industry 18.3
Dividend Yield (TTM)
--
52W High
$66.81
52W Low
$25.08
52W Range
6.0
F-Score
Modified Piotroski Analysis
Based on 10-year fundamentals
Strong • 6 / 9 points
Scoring Range (0-9)
8-9: Excellent Value
6-7: Strong Fundamentals
4-5: Average Quality
0-3: Weak Performance
Data Period: 2015-2024
Financial Dashboard
Q3 2025 Data
Revenue
$49.69B+0.00%
4-Quarter Trend
EPS
-$13.50+0.00%
4-Quarter Trend
FCF
$0.00+0.00%
4-Quarter Trend
Earnings Highlights
Key Highlights
No Data Available
Risk Factors
No Data Available
Outlook
No Data Available
Peer Comparison
Revenue (TTM)
CNC$178.19B
MOH$43.41B
FMS$21.22B
Gross Margin (Latest Quarter)
INCY93.5%
90.2%
89.0%
Key Metrics
Symbol | Market Cap | P/E (TTM) | ROE (TTM) | Debt to Assets |
|---|---|---|---|---|
| UTHR | $20.59B | 15.7 | 18.7% | 0.0% |
| WST | $20.49B | 41.9 | 17.7% | 7.7% |
| WAT | $20.44B | 30.9 | 35.0% | 32.6% |
Long-Term Trends
Last 4 Quarters
Revenue
Net Income
Operating Cash Flow
4-Quarter Revenue CAGR
+6.8%
Steady Growth
4-Quarter Net Income CAGR
N/M
Profitability Shift Observed
Cash Flow Stability
50%
Cash Flow Requires Attention
Research & Insights
Reports
All Years
Form 10-Q - Q2 2025
Period End: Jun 30, 2025|Filed: Jul 25, 2025|Revenue: $48.74B+22.4%|EPS: $-0.51-123.6%MissForm 10-Q - Q1 2025
Period End: Mar 31, 2025|Filed: Apr 25, 2025|Revenue: $46.62B+15.4%|EPS: $2.64+21.7%BeatForm 10-K - FY 2024
Period End: Dec 31, 2024|Filed: Feb 18, 2025|Revenue: $163.07B+5.9%|EPS: $6.33+27.4%BeatForm 10-Q - Q3 2024
Period End: Sep 30, 2024|Filed: Oct 25, 2024|Revenue: $42.02B+10.5%|EPS: $1.37+57.5%MeetForm 10-Q - Q2 2024
Period End: Jun 30, 2024|Filed: Jul 26, 2024|Revenue: $39.84B+5.9%|EPS: $2.16+11.9%MeetForm 10-Q - Q1 2024
Period End: Mar 31, 2024|Filed: Apr 26, 2024|Revenue: $40.41B+3.9%|EPS: $2.17+5.9%BeatForm 10-K - FY 2023
Period End: Dec 31, 2023|Filed: Feb 20, 2024|Revenue: $154.00B+6.5%|EPS: $4.97+137.8%BeatForm 10-Q - Q3 2023
Period End: Sep 30, 2023|Filed: Oct 24, 2023|Revenue: $38.04B+6.1%|EPS: $0.87-32.6%Miss